Deutsche Märkte schließen in 2 Stunden 5 Minuten

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
6,02+0,51 (+9,26%)
Börsenschluss: 04:00PM EDT
6,10 +0,08 (+1,33%)
Vorbörslich: 09:12AM EDT

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000
https://www.editasmedicine.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter265

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Dr. Gilmore O'Neill M.D.President, CEO & Director1,04MN/A1964
Mr. Erick J. Lucera C.F.A., CPACFO & Executive VP911,46kN/A1968
Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific Officer522,44kN/A1957
Dr. Baisong Mei M.D., Ph.D.Executive VP & Chief Medical Officer654,9kN/A1964
Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/AN/A
Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board MemberN/AN/A1954
Mr. Gregory WhiteheadExecutive VP and Chief Technical & Quality OfficerN/AN/AN/A
Cristi BarnettCorporate Communications & Investor RelationsN/AN/AN/A
Ms. Charlene Stern J.D., Ph.D.Executive VP & General CounselN/AN/AN/A
Ms. Linea AspesiExecutive VP & Chief People OfficerN/AN/A1970
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 2, Vorstand: 4, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.